skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

世界の医薬品産業に関する包括的なニュース配信サービス

Scrip
Scrip(スクリプ)は、インフォーマ・ファーマインテリジェンスが提供するニュース配信サービスの中でも、最も包括的に世界中の医療用医薬品と製薬産業全般に関するニュースを配信するサービスです。

今この瞬間にグローバルな医薬品産業で何が起きているのでしょうか。欧米のメガファーマやバイオベンチャーはどのような戦略を描いているのでしょうか。そして、それらの競争環境が御社のビジネスに与える影響は?

Scripは医薬品の研究開発や臨床試験に関する情報から、ライセンシングやディール活動、薬価政策に関するニュースまで幅広く取材しています。長年に渡り世界の医薬品産業を取材・分析・研究しているジャーナリストとアナリストが、単なる事実の報道ではない、御社の意思決定とビジネスの国際展開に役立つインテリジェンスをお届けします。

医薬品業界に従事される新入社員から経営層まで定番のニュースソースとしてお読みください。実際のScripのページへアクセスしていただくと、ログインせずに各記事の冒頭部分を読むことができます。

このサービスの特徴

無料の最新記事&レポート

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Biogen/Sage’s Zuranolone Data May Not Be Enough For Tough Commercial Landscape

    Depression_703104430_1200x675

    The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Novavax’s Latecomer COVID-19 Vaccine Impresses With 90% Efficacy Result

    NovavaxFlag

    Arriving two to three months later than planned, Novavax’s nanoparticle-based vaccine is still a welcome addition to the field, for both rich and poor countries.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: a ground-breaking approval for Alzheimer’s in the US; LAG-3 inhibitors and new Keytruda data generate excitement at ASCO; and clinical progress for another COVID-19 vaccine.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    IQVIA Biotech’s Sockalingam On Clinical Research Virtualization In APAC

    SC2105_Generic_Podcast_Image_1200

    In this audio interview, the head of IQVIA Biotech (Japan-Asia Pacific) talks to Scrip on a range of aspects around digitalization and virtualization of clinical research in the region, including sharply reduced site contracting timelines. He also touches on the digital product launch efforts that are currently a reality in several markets.

  • 世界の薬事規制動向&情報を配信, Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Drug Pricing eBook

    Tap into expert coverage of the complex world of drug pricing with insights from analysts at Scrip and Pink Sheet. This eBook includes vital information about issues affecting drug pricing for the US, EU, and other global markets, including patient access, regulatory issues, commercial challenges, value-based pricing, and more.

    Topic drug-pricing

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    UK Trial Could Help Pick Best Covid Vaccine Boosters

    UK_Bolton_Vaccination_1200

    Results will be important in fight against new variants, for second-generation vaccines and AstraZeneca’s controversy-hit jab.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast episode of Five Must-Know Things, hear about GSK coming under pressure from investors; BMS focusing on a promising oncology target in a new deal; Sanofi’s COVID-19 vaccine challenges; China's progress with mRNA coronavirus vaccines; and new headwinds for Pfizer’s Ibrance.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Five Late-Breakers To Watch For At ASCO 2021

    Cancer_DNA_testube_1077882071_1200

    This year’s American Society of Clinical Oncology meeting is set to take place virtually from 4-8 June, and while many abstracts have now been released for this year’s conference, we take a sneak peek at what is still under wraps, with five of the key late-breaking presentations due to be presented at the plenary session, with input from Biomedtracker and Datamonitor Healthcare.    

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Credit Where It Is Due: Pfizer’s COVID-19 Vaccine Smashes Launch Records As Expected

    SC2104_Record_breaking_KP9T6F

    Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Will Beovu Be A Slow-Burning Blockbuster?

    SC1901_Spy_1155740245_1200

    Expanded indications will be key for Novartis's Beovu and a successful diabetic macular edema trial has provided a fillip, a week after the wet AMD-approved drug posted a 44% slump in sales.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Raising Corporate Taxes Would Put US Investment At Risk, J&J CFO Warns

    SC2104_Taxes_WT8695_1200

    J&J employs 3,000 more people today than it did before US corporate tax reform in 2017, CFO Wolk said, highlighting the company's US investments.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast version of Five Must-Know Things, hear about adenovirus vaccines and blood clots, Lilly’s new moves in genetic diseases, the efficacy debate over Chinese COVID-19 vaccines, putting a price tag on innovation, and Sanofi’s bullishness on IL-2.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    #ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity

    CLINICALTRIALS_KENARY820_571088092_1200x675

    Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Will AZ Legal Notice, Clotting Incidents Cloud Serum’s Fortunes?

    SC2104_BusinessMisfortuneConcept_329959043_1200

    AstraZeneca has sent a legal notice to Indian partner Serum Institute for non-delivery of COVID-19 vaccines. Will this and the entry of a new challenger, Sputnik V, in the Indian market affect Serum’s fortunes? Will the EMA and MHRA announcement on clotting incidents related to the AZ vaccine shrink demand for the partnered vaccine?

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    AACR Round-Up: Zentalis, Pieris, Hookipa And Eli Lilly

    SC2104_cancercell_536117299-1200

    Zentalis outlines promising antitumor activity associated with its WEE1 inhibitor, Phase II trials are planned for Pieris Pharmaceuticals’ fusion protein in HER2-positive cancers, while HPV-positive cancers are being targeted by Hookipa’s immunotherapeutics in arenavirus vectors, and Eli Lilly is planning early-stage clinical trials with its next-generation KRAS inhibitor.  

医薬品産業専門のジャーナリスト&アナリスト

Editor

Brenda Sandburg

Editor, Senior Editor

New York, USA

Brenda Sandburg

Brenda specializes in

  • Policy and Regulation
  • Biosimilars
  • Biotech
  • Generics
  • Pricing

+39 year(s) experience

Editor

Cathy Kelly

Editor, Senior editor

Washington DC, USA

Cathy Kelly
Management

Denise Peterson

Management, Editor In Chief, Pharma US

Washington DC, USA

Denise Peterson

無料トライアル&お問い合わせ

ニュースサービスでは無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問い合わせの際は下記のフォームまたはメールアドレスをご利用下さい。

Eメール:inquiry.jp@informa.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。